Galectin Therapeutics (GALT) Other Non-Current Liabilities (2010 - 2026)

Galectin Therapeutics' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 2090.44% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a 2090.44% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 4114.89% from the prior year.
• Other Non-Current Liabilities slipped to $3.0 million in Q1 2026 per GALT's latest filing, from $4.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.0 million in Q4 2025 and bottomed at $94000.0 in Q1 2024.
• The 5-year median for Other Non-Current Liabilities is $341000.0 (2022), against an average of $804625.0.
• Across the five-year window, Other Non-Current Liabilities slumped 80.38% in 2024 and jumped 4114.89% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $214000.0 in 2022, then surged by 101.4% to $431000.0 in 2023, then slumped by 78.19% to $94000.0 in 2024, then soared by 4114.89% to $4.0 million in 2025, then decreased by 24.81% to $3.0 million in 2026.
• Per Business Quant, the three latest GALT Other Non-Current Liabilities figures stand at $3.0 million (Q1 2026), $4.0 million (Q4 2025), and $1.5 million (Q2 2025).